Encore Medical, Inc.

FWP supplemental

Price $5.00 · 3,000,000 shares · Gross proceeds $15,000,000

S-1/A amended

Price $5.00 · 3,000,000 shares · Gross proceeds $15,000,000

FWP supplemental

Price $5.00 · Range $5.00 to $5.00 · 3,000,000 shares · Gross proceeds $15,000,000

S-1/A amended

Encore Medical, Inc. filed an S-1/A registration statement amendment, adding exhibits such as the Filing Fee Table and a 2021-2022 Investor’s Warrant. The filing highlights the company's PFO closure device, targeting markets for stroke and migraine treatments, with ongoing FDA trials and commercialization in Europe. The amendment reflects updates to the IPO registration process, including legal and financial disclosures.

FWP supplemental

Price $5.00 · 3,000,000 shares · Gross proceeds $15,000,000

Encore Medical, Inc. is preparing for its initial public offering (IPO) with a focus on its PFO closure device, targeting the $1.5B+ stroke market and $100B+ migraine market. The filing supersedes a prior Free Writing Prospectus, emphasizing clinical trials, regulatory pathways, and market expansion. Key highlights include a head-to-head FDA-approved trial, CE marking, and $2.5M in 2025 Europe sales. The offering aims to raise $15M (plus over-allotment) for clinical trials, commercial growth, and debt reduction.

FWP supplemental

Price $5.00 · 3,000,000 shares · Gross proceeds $15,000,000

Encore Medical, Inc. is conducting an initial public offering (IPO) for its PFO closure device, targeting the $1.5B+ stroke market and $100B+ migraine headache market. The company highlights its differentiated technology with superior clinical outcomes, CE marking, and ongoing FDA trials. The offering aims to raise $15 million (plus over-allotment) to fund clinical trials, commercial growth, debt reduction, and working capital. The device has demonstrated high closure rates and minimal metal usage, with 35,000+ implants globally. The IPO follows regulatory progress in Europe and pending U.S. FDA approval.

S-1/A amended

Price $5.00 · 3,000,000 shares · Gross proceeds $15,000,000

Encore Medical, Inc. is conducting an IPO to raise capital for clinical development of stroke and migraine indications, working capital, and debt repayment. The company plans to allocate $7.2M for stroke trials, $2M for migraine programs, and use remaining proceeds for commercialization, equipment, and debt obligations. While the IPO proceeds are expected to cover stroke trials and initial milestones, additional capital may be required for migraine development. The offering also includes a potential over-allotment option to increase proceeds.

S-1/A amended

Price $5.00 · 3,000,000 shares · Gross proceeds $15,000,000

Encore Medical, Inc. is conducting an amended S-1/A filing to raise approximately $12.7 million (or $14.65 million if underwriters exercise over-allotment) through an IPO at $5.00 per share. The proceeds will fund clinical development for stroke and migraine indications, with $7.2M allocated to stroke trials and $2M to migraine programs. Additional funds will support commercialization, equipment purchases, and repayment of a $1M loan to Merit Medical Systems. The company acknowledges potential need for additional capital to complete migraine trials and emphasizes uncertainty in meeting development timelines.

S-1/A amended

Price $5.00 · 3,000,000 shares · Gross proceeds $15,000,000

Encore Medical, Inc. is conducting an IPO to raise capital for clinical development, particularly for stroke and migraine indications, with $7.2 million allocated for stroke trials and $2.0 million for migraine programs. The company expects proceeds to cover clinical trial activities and commercialization efforts but may require additional funding for later-stage migraine trials. The offering aims to strengthen financial flexibility, with net proceeds estimated at $12.96 million (or $14.88 million with full over-allotment), and outlines detailed use-of-proceeds breakdowns and capitalization scenarios.

S-1 filed

Encore Medical, Inc. is conducting an initial public offering (IPO) to raise capital for clinical trials focused on stroke and migraine indications, working capital, and general corporate purposes. The company plans to convert its Series A Preferred Stock into common stock prior to the offering, eliminating associated rights and preferences. The filing highlights risks including reliance on clinical trial outcomes, regulatory changes, litigation exposure, IT system capabilities, compliance requirements, need for additional financing, stock price volatility, and significant dilution for new investors. The company has not paid dividends and does not intend to do so in the foreseeable future.